NCT05556616 2026-01-29iinnovate-2Teva Branded Pharmaceutical Products R&D, Inc.Phase 1 Terminated15 enrolled 15 charts
NCT04714372 2024-10-24FT538 in Combination With Daratumumab in AML Acute Myeloid LeukemiaMasonic Cancer Center, University of MinnesotaPhase 1 Completed9 enrolled 16 charts